NASDAQ:FNCH

Finch Therapeutics Group Stock Forecast, Price & News

$17.00

-0.10 (-0.58 %)

(As of 04/13/2021 12:00 AM ET)

Add

Compare

Today's Range

$15.90

Now: $17.00▼

$18.59

50-Day Range N/A

52-Week Range

$15.27

Now: $17.00▼

$22.50

Volume118,741 shs

Average Volume257,346 shs

Market Capitalization$801.47 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, engages in developing a novel class of orally administered biological drugs in the United States. Its lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection. The company is also developing CP101 for the chronic hepatitis B; FIN-211, an orally administered enriched consortia product candidate for the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. Finch Therapeutics Group, Inc. is based in Somerville, Massachusetts.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:FNCH

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.finchtherapeutics.com

Phone617-229-6499

Employees131

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares47,145,000

Market Cap$801.47 million

Next Earnings DateN/A

OptionableNot Optionable

Headlines

Finch Therapeutics Group (NASDAQ:FNCH) Shares Gap Up to $17.10
April 13, 2021 | americanbankingnews.com

Finch Therapeutics Group (NASDAQ:FNCH) Research Coverage Started at Evercore ISI
April 13, 2021 | americanbankingnews.com

Finch Therapeutics Group (NASDAQ:FNCH) Now Covered by Jefferies Financial Group
April 13, 2021 | americanbankingnews.com

Bank of America Begins Coverage on Finch Therapeutics Group (NASDAQ:FNCH)
April 13, 2021 | americanbankingnews.com

Finch Therapeutics Group (NASDAQ:FNCH) Stock Price Up 5.2%
April 7, 2021 | americanbankingnews.com

29 finches sealed inside hair rollers discovered in man's luggage as he arrives in US
March 31, 2021 | msn.com

News for Finch Therapeutics Group Inc Registered Shs
March 26, 2021 | markets.businessinsider.com

Jeffery A. Smisek Buys 88,235 Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Stock
March 25, 2021 | americanbankingnews.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.33 out of 5 stars

Medical Sector

757th out of 2,019 stocks

Biotechnology Industry

34th out of 145 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Finch Therapeutics Group.

5.0 Community Rank

Outperform Votes
Finch Therapeutics Group has received 3 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Finch Therapeutics Group has received 0 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Finch Therapeutics Group has received 100.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Finch Therapeutics Group and other stocks. Vote “Outperform” if you believe FNCH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FNCH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Finch Therapeutics Group does not currently pay a dividend.
Dividend Growth
Finch Therapeutics Group does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Finch Therapeutics Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,499,995.00 in company stock and sold $0.00 in company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$17.00

-0.10 (-0.58 %)

(As of 04/13/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive FNCH News and Ratings via Email

Sign-up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.

Finch Therapeutics Group (NASDAQ:FNCH) Frequently Asked Questions

What stocks does MarketBeat like better than Finch Therapeutics Group?

Wall Street analysts have given Finch Therapeutics Group a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Finch Therapeutics Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Finch Therapeutics Group's key executives?

Finch Therapeutics Group's management team includes the following people:

Mr. Mark Burnham Smith, CEO, Pres & Director
Mr. Gregory D. Perry, CFO & Treasurer (Age 61)
Ms. Kristine Callahan CPA, Sr. Director of Accounting
Ms. Sonia Timberlake, Sr. VP of Research
Mr. Andrew Noh, Chief Admin. Officer & Sec.
Mr. Joseph D. Vittiglio J.D., Esq., Gen. Counsel (Age 49)
Mr. James S. Sigler, Exec. VP of CMC (Age 60)
Mr. Zain Kassam, Chief Medical Officer
Mr. Kris Piper M.S., Sr. VP of Regulatory & Quality Assurance
Dr. Michelle L. Rose, Chief Regulatory Officer

Who are some of Finch Therapeutics Group's key competitors?

Some companies that are related to Finch Therapeutics Group include MorphoSys (MOR), Nuvation Bio (NUVB), ImmunityBio (IBRX), BioAtla (BCAB), Immunocore (IMCR), Cullinan Oncology (CGEM), Cricut (EWTX), Trillium Therapeutics (TRIL), Kinnate Biopharma (KNTE), Concordia International (CXR), Silverback Therapeutics (SBTX), PureTech Health (PRTC), Nurix Therapeutics (NRIX), Vor Biopharma (VOR) and 4D Molecular Therapeutics (FDMT).
View all of FNCH's competitors.

When did Finch Therapeutics Group IPO?

(FNCH) raised $101 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO.

What is Finch Therapeutics Group's stock symbol?

Finch Therapeutics Group trades on the NASDAQ under the ticker symbol "FNCH."

When does the company's quiet period expire?

Finch Therapeutics Group's quiet period expires on Wednesday, April 28th. Finch Therapeutics Group had issued 7,500,000 shares in its IPO on March 19th. The total size of the offering was $127,500,000 based on an initial share price of $17.00. During the company's quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Finch Therapeutics Group?

Shares of FNCH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Finch Therapeutics Group's stock price today?

One share of FNCH stock can currently be purchased for approximately $17.00.

How much money does Finch Therapeutics Group make?

Finch Therapeutics Group has a market capitalization of $801.47 million.

How many employees does Finch Therapeutics Group have?

Finch Therapeutics Group employs 131 workers across the globe.

What is Finch Therapeutics Group's official website?

The official website for Finch Therapeutics Group is www.finchtherapeutics.com.

How can I contact Finch Therapeutics Group?

The company can be reached via phone at 617-229-6499.

This page was last updated on 4/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Finch Therapeutics Group Stock Forecast, Price & News

Adding

Adding

Adding Finch Therapeutics Group, Inc.

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Headlines

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

5.0 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment